ESMO 2024: TROP2-directed ADCs show promise in recurrent gynecological cancers
Platinum-based therapies are mainstay for endometrial and ovarian cancers but often recur. Antibody drug conjugates (ADCs) like Elahere and datopotamab deruxtecan (Dato-DXd) show promise, with Dato-DXd demonstrating improved outcomes in recurrent EC and OC at ESMO 2024. Dato-DXd's efficacy and safety profile, along with a convenient dosing schedule, position it as a potential preferred treatment over competitors like Merck's sacituzumab govitecan (Sac-TMT), which also shows comparable efficacy in heavily pretreated patients. Both TROP2-directed ADCs offer hope for challenging gynecological cancers.
Reference News
Platinum-based therapies are mainstay for endometrial and ovarian cancers but often recur. Antibody drug conjugates (ADCs) like Elahere and datopotamab deruxtecan (Dato-DXd) show promise, with Dato-DXd demonstrating improved outcomes in recurrent EC and OC at ESMO 2024. Dato-DXd's efficacy and safety profile, along with a convenient dosing schedule, position it as a potential preferred treatment over competitors like Merck's sacituzumab govitecan (Sac-TMT), which also shows comparable efficacy in heavily pretreated patients. Both TROP2-directed ADCs offer hope for challenging gynecological cancers.